The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer

References

• Shepherd FA, Hirsh V, Smylie M, et al. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer. N Engl J Med. 2005;353(2):123–132. .
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527–1537. .
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Okimoto RA, Supko JG, et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib. N Engl J Med. 2004;350(21):2129–2139. .
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500. .
   PubMed Web of Science ®Google Scholar
• Shi Y, Au JS-K, Thongprasert S, et al. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). J Thorac Oncol. 2014;9(2):154–162. .
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. N Engl J Med. 2009;361(10):958–967. .
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209-249.
   Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246. .
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC-H, Yamamoto N, et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. J Clin Oncol. 2013;31(27):3327–3334. .
   PubMed Web of Science ®Google Scholar
• Makoto M, Akira I, Kunihiko K, et al., Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med. 362(25): 2380–2388. 2010. .
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–128. .
   PubMed Web of Science ®Google Scholar
• Chen G, Feng J, Zhou C, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol. 2013;24(6):1615–1622. .
   PubMed Web of Science ®Google Scholar
• Lin JJ, Cardarella S, Lydon CA, et al. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol. 2016;11(4):556–565. .
   PubMed Web of Science ®Google Scholar
• Westover D, Zugazagoitia J, Cho BC, et al. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29:i10–i19.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al., Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer. N Engl J Med. 376(7): 629–640. 2017. .
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated,EGFR -Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41–50. .
   PubMed Web of Science ®Google Scholar
• Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113–125. .
   PubMed Web of Science ®Google Scholar
• Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR -mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725–737. .
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Yang JC-H, Yu H, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020;31(4):507–516. .
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186.
   PubMed Web of Science ®Google Scholar
• Jackson AL, Zhou B, Kim WY. HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert Opin Ther Targets. 2010;14(10):1047–1057.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber H-P LJ. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol. 2005;23(14):3243–3256.
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer. N Engl J Med. 2006;355(24):2542–2550. .
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–673. .
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184–2191. .
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–155. .
   PubMed Web of Science ®Google Scholar
• Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011;377(9780):1846–1854. .
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Cohen RB, Eadens M, et al., Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G 1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2. JCO. 28(5): 780–787. 2010. .
   PubMed Web of Science ®Google Scholar
• Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci. 2005;109(3):227–241.
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Hurwitz HI, Cohen RB, et al. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol. 2015;26(6):1230–1237. .
   PubMed Web of Science ®Google Scholar
• Pore N, Jiang Z, Gupta A, et al. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 2006;66(6):3197–3204. .
   PubMed Web of Science ®Google Scholar
• Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 2002;62:2554–2560.
   PubMed Web of Science ®Google Scholar
• Nilsson MB, Robichaux J, Herynk MH, et al. Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. J Thorac Oncol. 2021;16(3):439–451. .
   PubMed Web of Science ®Google Scholar
• Viloria-Petit A, Crombet T, Jothy S, et al. Acquired Resistance to the Antitumor Effect of Epidermal Growth Factor Receptor-blocking Antibodies in Vivo: a Role for Altered Tumor Angiogenesis. Cancer Res. 2001;61:5090–5101.
   PubMed Web of Science ®Google Scholar
• Masuda C, Yanagisawa M, Yorozu K, et al. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model. Int J Oncol. 2017;51(2):425–434. .
   PubMed Web of Science ®Google Scholar
• Ninomiya T, Takigawa N, Ichihara E, et al. Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model. Mol Cancer Ther. 2013;12(5):589–597. .
   PubMed Web of Science ®Google Scholar
• Kayatani H, Ohashi K, Imao T, et al. Abstract 5198: combination effect of anti-VEGFR-2 antibody with erlotinib on EGFR mutant non-small cell lung cancer. Cancer Res. 2016;76:5198.
   Web of Science ®Google Scholar
• Abid MR, Shaodong G, Takashi M, et al. Vascular Endothelial Growth Factor Activates PI3K/Akt/Forkhead Signaling in Endothelial Cells. Arterioscler Thromb Vasc Biol. 2004;24(2):294–300. .
   PubMed Web of Science ®Google Scholar
• Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 1999;18(13):2221–2230.
   PubMed Web of Science ®Google Scholar
• Rosell R, Dafni U, Felip E, et al., Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 5(5): 435–444. 2017. .
   PubMed Web of Science ®Google Scholar
• Ichihara E, Hotta K, Nogami N, et al. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. J Thorac Oncol. 2015;10(3):486–491. .
   PubMed Web of Science ®Google Scholar
• Seto T, Kato T, Nishio M, et al., Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 15(11): 1236–1244. 2014. .
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Seto T, Nishio M, et al. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: survival follow-up results of the randomized JO25567 study. Lung Cancer. 2021;151:20–24.
   PubMed Web of Science ®Google Scholar
• Saito H, Fukuhara T, Furuya N, et al., Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 20(5): 625–635. 2019. .
   PubMed Web of Science ®Google Scholar
• Zhou Q, Wu Y-L, Cheng Y, et al. 1480O - CTONG 1509: phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC. Ann Oncol. 2019;30:v603.
   Web of Science ®Google Scholar
• Landre T, Des Guetz G, Chouahnia K, et al. First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation. J Cancer Res Clin Oncol. 2020;146(12):3333–3339. .
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Garon EB, Seto T, et al., Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20(12): 1655–1669. 2019. .
   PubMed Web of Science ®Google Scholar
• Jenkins S, Yang JC-H, Ramalingam SS, et al. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer. J Thorac Oncol. 2017;12(7):1061–1070. .
   PubMed Web of Science ®Google Scholar
• Yoh K, Atagi S, Reck M, et al. Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR -mutated metastatic non-small-cell lung cancer. Curr Med Res Opin. 2020;36(10):1667–1675. .
   PubMed Web of Science ®Google Scholar
• Liu Q, Luo X, Peng L, et al. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China. BMJ Open. 2020;10(11):e040691. .
   PubMed Web of Science ®Google Scholar
• Akamatsu H, Ozawa Y, Oyanagi J, et al. Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation. Anticancer Res. 2021;41(2):911–917. .
   PubMed Web of Science ®Google Scholar
• Lu Z-Q, Cai J, Wang X, et al. Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR -mutation non-small cell lung cancer: a phaseII single-arm prospective clinical trial. Thorac Cancer. 2021;12(2):172–180. .
   PubMed Web of Science ®Google Scholar
• Yu HA, Schoenfeld AJ, Makhnin A, et al. Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR -Mutant Lung Cancers. JAMA Oncol. 2020;6(7):1048–1054. .
   PubMed Web of Science ®Google Scholar
• Noronha V, Patil VM, Joshi A, et al. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. J Clin Oncol. 2020;38(2):124–136. .
   PubMed Web of Science ®Google Scholar
• Hosomi Y, Morita S, Sugawara S, et al., Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. JCO. 38(2): 115–123. 2019. .
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Nadal E, Garon EB, et al. RELAY subgroup analyses by EGFR ex19del and ex21L858R mutations for ramucirumab plus erlotinib in metastatic non-small cell lung cancer. Clin Cancer Res 2021 Jul 22:clincanres.0273.2021. doi:https://doi.org/10.1158/1078-0432.CCR-21-0273.
   Google Scholar